Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
mi
from
Little Rock, AR
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Pacific Clinical Research Medical Group
mi
from
Orange, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Pacific Clinical Research Medical Group
mi
from
Orange, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Catalina Research Institute
mi
from
Chino, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Catalina Research Institute
mi
from
Chino, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Pharmacology Research Institute
mi
from
Newport Beach, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Pharmacology Research Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Behavioral Research Specialists, LLC
mi
from
Glendale, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Behavioral Research Specialists, LLC
mi
from
Glendale, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
California Neuropsychopharmacology Clinical
mi
from
San Diego, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
California Neuropsychopharmacology Clinical
mi
from
San Diego, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Sharp Mesa Vista Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Pacific Research Network
mi
from
San Diego, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Pacific Research Network
mi
from
San Diego, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Affiliated Research Institute
mi
from
San Diego, CA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Affiliated Research Institute
mi
from
San Diego, CA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Western Affiliated Research Institute
mi
from
Denver, CO
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Western Affiliated Research Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Radiant Research, Inc.
mi
from
Denver, CO
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Radiant Research, Inc.
mi
from
Denver, CO
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Gulfcoast Clinical Research Center
mi
from
Fort Myers, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Gulfcoast Clinical Research Center
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Amit Vijapura
mi
from
Jacksonville, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Amit Vijapura
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Compass Research LLC
mi
from
Orlando, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Stedman Clinical Trials
mi
from
Tampa, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Emory University
mi
from
Atlanta, GA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Atlanta Institute of Medicine and Research
mi
from
Atlanta, GA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Atlanta Institute of Medicine and Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Comprehensive Clinical Development, Inc.
mi
from
Atlanta, GA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Comprehensive Clinical Development, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Carman Research
mi
from
Smyrna, GA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Carman Research
mi
from
Smyrna, GA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Alpine Clinic
mi
from
Lafayette, IN
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Alpine Clinic
mi
from
Lafayette, IN
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Clinical Trials Technology, Inc
mi
from
Prairie Village, KA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Clinical Trials Technology, Inc
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
James G. Barbee, Md, Llc
mi
from
New Orleans, LA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
James G. Barbee, Md, Llc
mi
from
New Orleans, LA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
J. Gary Booker, MD APMC
mi
from
Shreveport, LA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
J. Gary Booker, MD APMC
mi
from
Shreveport, LA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
McLean Hospital
mi
from
Belmont, MA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
McLean Hospital
mi
from
Belmont, MA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Bio Behavioral Health
mi
from
Toms River, NJ
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Bio Behavioral Health
mi
from
Toms River, NJ
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Albuquerque Neuroscience Inc.
mi
from
Albuquerque, NM
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Albuquerque Neuroscience Inc.
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
SPRI Clinical Trials LLC
mi
from
Brooklyn, NY
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
SPRI Clinical Trials LLC
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Village Clinical Research Inc.
mi
from
New York, NY
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Village Clinical Research Inc.
mi
from
New York, NY
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Finger Lakes Clinical Research
mi
from
Rochester, NY
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Finger Lakes Clinical Research
mi
from
Rochester, NY
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Carolinas HealthCare System
mi
from
Charlotte, NC
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Carolinas HealthCare System
mi
from
Charlotte, NC
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Richard H. Weisler, Md, Pa & Assoc.
mi
from
Raleigh, NC
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Richard H. Weisler, Md, Pa & Assoc.
mi
from
Raleigh, NC
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Northcoast Clinical Trials
mi
from
Beachwood, OH
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Northcoast Clinical Trials
mi
from
Beachwood, OH
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Midwest Clinical Research Center
mi
from
Dayton, OH
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Midwest Clinical Research Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Neurology & Neuroscience Center of Ohio
mi
from
Toledo, OH
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Neurology & Neuroscience Center of Ohio
mi
from
Toledo, OH
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
IPS Research Company
mi
from
Oklahoma City, OK
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Tulsa Clinical Research
mi
from
Tulsa, OK
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Tulsa Clinical Research
mi
from
Tulsa, OK
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Oregon Center for Clinical Investigations, Inc (OCCI, Inc.)
mi
from
Portland, OR
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Oregon Center for Clinical Investigations, Inc (OCCI, Inc.)
mi
from
Portland, OR
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Summit Research Network (Oregon) Inc.
mi
from
Portland, OR
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Summit Research Network (Oregon) Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
mi
from
Salem, OR
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
mi
from
Salem, OR
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Suburban Research Associates
mi
from
Media, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Suburban Research Associates
mi
from
Media, PA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Keystone Clinical Studies, Llc
mi
from
Norristown, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Keystone Clinical Studies, Llc
mi
from
Norristown, PA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Univ Of Penn
mi
from
Philadelphia, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Univ Of Penn
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated:  9/23/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression
Status: Enrolling
Updated: 9/23/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials